Terns Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Terns Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-39.9%
Buyback Yield
| Total Shareholder Yield | -39.9% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Terns Pharmaceuticals: Another Potential GLP-1 Entrant
Oct 21Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Sep 25Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive
Sep 10We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Aug 18
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
May 03Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03Terns Pharmaceuticals: The Easy Money Has Been Made
Sep 20Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08
Aug 08Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study
Jun 14Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TERN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TERN's dividend payments have been increasing.
Dividend Yield vs Market
| Terns Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (TERN) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (TERN) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate TERN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TERN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate TERN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TERN has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 23:02 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Terns Pharmaceuticals, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Corinne Johnson | Goldman Sachs |
| Corinne Johnson | Goldman Sachs |